ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization
Showcasing at AAO 2025: NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING…
HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease
HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by…
New Imprivata Report Finds that Australian Hospitals Save More Than $1.2 Million AUD Annually with Shared-Use Mobile Devices, but Strategic Gaps Still Pose Security and Operational Risk
MELBOURNE, Australia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Imprivata, a leading provider of…
TriNetX Named Among the Top 25 Healthcare Software Companies of 2025
Recognition by The Healthcare Technology Report underscores TriNetX's innovation in real-world data,…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
MindHYVE.ai Unveils ChironAI: The World’s First AGI-Powered Clinical Decision Support System, Redefining Healthcare Intelligence
NEWPORT BEACH, Calif., Sept. 24, 2025 /PRNewswire/ -- HYVE Labsâ„¢ and MindHYVE.aiâ„¢…
Alira Health Becomes First Platinum CRO Partner of the Wound Care Collaborative Community, Expanding Ongoing Work to Advance Wound Healing Innovation
FRAMINGHAM, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Alira Health announced today…
Osstem Implant Expands World-Class Clinical Education in India, Accelerating CSR Efforts
OIC India Enhances On-Site Capabilities with Structured Clinical and Digital Dentistry Training…
Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting
NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the Multiple Myeloma…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…